A5047999265- Parkinson's Disease Mechanisms and Treatments
- Neurotransmitter Receptor Influence on Behavior
- Neuroscience and Neuropharmacology Research
- Neurological disorders and treatments
- Nerve injury and regeneration
- Neuroinflammation and Neurodegeneration Mechanisms
- Peroxisome Proliferator-Activated Receptors
- Adenosine and Purinergic Signaling
- Receptor Mechanisms and Signaling
- Nuclear Receptors and Signaling
- Botulinum Toxin and Related Neurological Disorders
- Tryptophan and brain disorders
- Adipose Tissue and Metabolism
- Neuropeptides and Animal Physiology
- Alzheimer's disease research and treatments
- Stress Responses and Cortisol
- Metabolism and Genetic Disorders
- Regulation of Appetite and Obesity
- Mitochondrial Function and Pathology
- Conducting polymers and applications
- Biochemical Analysis and Sensing Techniques
- Eicosanoids and Hypertension Pharmacology
- Treatment of Major Depression
- Fungal Plant Pathogen Control
- Neurogenesis and neuroplasticity mechanisms
University of Cagliari
2014-2024
Neuroscience Institute
2012-2020
National Institute of Mental Health
1999-2000
National Institutes of Health
1999
Sigma Tau (Italy)
1991
Several studies indicate that the size of body fat stores and circulating levels adipocyte-derived hormone leptin are able to influence activity hypothalamic-pituitary-gonadal axis. The leptin-hypothalamic-pituitary-gonadal interactions have been mainly studied at level central nervous system. In this study, we investigated possibility may direct effects on rodent Leydig cell function. To probe hypothesis, first analyzed expression receptors (OB-R) in cells culture. RT-PCR showed rat express...
Abstract Rosiglitazone is a commonly prescribed insulin‐sensitizing drug with selective agonistic activity on the peroxisome proliferator‐activated receptor‐gamma (PPAR‐γ). PPAR‐γ can modulate inflammatory responses in brain, and agonists might be beneficial neurodegenerative diseases. In present study we used chronic 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine plus probenecid (MPTPp) mouse model of progressive Parkinson’s disease (PD) to assess therapeutic efficacy rosiglitazone...
Background and Purpose Microglial phenotype phagocytic activity are deregulated in Parkinson's disease (PD). PPARγ agonists neuroprotective experimental PD, but their role regulating microglial phagocytosis has been poorly investigated. We addressed it by using the agonist MDG548. Experimental Approach Murine cell line MMGT12 was stimulated with LPS and/or MDG548, effect on of fluorescent microspheres or necrotic neurons investigated flow cytometry. Cytokines markers microglia phenotype,...
Thalidomide and closely related analogues are used clinically for their immunomodulatory antiangiogenic properties mediated by the inhibition of proinflammatory cytokine tumor necrosis factor α. Neuroinflammation angiogenesis contribute to classical neuronal mechanisms underpinning pathophysiology l-dopa-induced dyskinesia, a motor complication associated with l-dopa therapy in Parkinson's disease. The efficacy thalidomide more potent derivative 3,6'-dithiothalidomide on dyskinesia was...
Parkinson's disease (PD) diagnosis is still vulnerable to bias, and a definitive often relies on post-mortem neuropathological diagnosis. In this regard, alpha-synuclein (αsyn)-specific in vivo biomarkers remain critical unmet need, based its relevance the neuropathology. Specifically, content changes αsyn species such as total (tot-αsyn), oligomeric (o-αsyn), phosphorylated (p-αsyn) within cerebrospinal fluid (CSF) peripheral fluids (i.e., blood saliva) have been proposed PD possibly...
Abstract Cell signaling is central to neuronal activity and its dysregulation may lead neurodegeneration cognitive decline. Here, we show that selective genetic potentiation of ERK prevents cell death in vitro vivo the mouse brain, while attenuation does opposite. This neuroprotective effect mediated by an enhanced nuclear can also be induced novel penetrating peptide RB5. In administration RB5 disrupts preferential interaction ERK1 MAP kinase with importinα1/KPNA2 over ERK2, facilitates...
Adenosine A(2A) receptors antagonists produce neuroprotective effects in animal models of Parkinson's disease (PD). As neuroinflammation is involved PD pathogenesis, both neuronal and glial might participate to neuroprotection. We employed complementary pharmacologic genetic approaches receptor inactivation, a multiple MPTP mouse model PD, investigate the cellular basis neuroprotection by antagonism. MPTP.HCl (20 mg/kg daily for 4 days) was administered mice treated with antagonist SCH58261,...
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)- γ agonists commonly used as insulin-sensitizing drugs for the treatment of type 2 diabetes. In last decade, PPAR- have received increasing attention their neuroprotective properties displayed in a variety neurodegenerative diseases, including Parkinson's disease (PD), likely related to anti-infammatory activity these compounds. Recent studies indicate that neuroinflammation, specifically reactive microglia,...
Currently, there are no effective therapeutic options for Alzheimer's disease, the most common, multifactorial form of dementia, characterized by anomalous amyloid accumulation in brain. Growing evidence points to neuroinflammation as a major promoter AD. We have previously shown that proinflammatory cytokine TNFSF10 fuels AD neuroinflammation, and its immunoneutralization results improved cognition 3xTg-AD mouse. Here, we hypothesize inflammatory hallmarks might parallel with central...
Progesterone is a sex hormone which shows neuroprotective effects in different neurodegenerative disorders, including Parkinson's disease, stroke, and Alzheimer's disease. However, the pharmacokinetic limitations associated with peripheral administration of this molecule highlight need for more efficient delivery approaches to increase brain progesterone levels. Since nose-to-brain mucoadhesive hydrogel nanoparticles non-invasive convenient strategy therapeutics central nervous system, work,...